AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
One-year-old Israeli AI startup with six employees acquired for estimated $100 million
2
Israel’s hypersonic interceptor goes public as the U.S. and Iran race to develop advanced missiles
3
Wiz billionaires emerge as frontrunners for McDonald’s Israel franchise
4
Palo Alto CEO Nikesh Arora secures $147 million upfront through share-linked deal
5
CrowdStrike in advanced talks to acquire Israeli startup Orion for $500 million
More news

Copaxone

5 stories about Copaxone
מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
default image

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
Previous Articles